🥗 Nutrigenomics Personalized Diet Optimizer

From Saliva to Sequence — Genome-Wide SNP Genotyping for Nutrition

Nutrigenomics begins with accurate, reproducible genotyping of single-nucleotide polymorphisms (SNPs) known to modulate nutrient metabolism. Consumer and clinical panels typically use SNP microarrays rather than full whole-genome sequencing, trading comprehensive coverage for cost (~$50-150) and turnaround (3-10 days) while still capturing the handful of well-replicated nutrition-relevant loci.

• ~650k: SNPs on standard array (Illumina Infinium Global Screening Array)
• >99.7%: Genotype call accuracy (at 30x equivalent depth)
• ~120: Nutrition-relevant loci curated (GWAS Catalog, replicated ≥2 cohorts)
• 3–10 days: Turnaround time (saliva kit to report)

Genotyping technology and variant calling pipeline

Sample collection & DNA extraction: • Saliva (Oragene kit) or buccal swab; yields 2–10 µg genomic DNA • Silica-column extraction; A260/280 ratio 1.7–2.0 required for array hybridization

Microarray genotyping (Illumina Infinium chemistry): • Whole-genome amplification → fragmentation → hybridization to bead-bound 50-mer probes • Single-base extension with labeled ddNTP → fluorescence read by iScan • ~650,000 probes per array; GenCall score >0.15 required per call

Variant calling & QC: • Cluster file (GenTrain) separates AA/AB/BB genotype clusters per SNP • Sample-level QC: call rate >98%, heterozygosity within 3 SD of cohort mean • Imputation (optional): reference panel (1000 Genomes/TOPMed) extends coverage to ~40M variants via linkage disequilibrium

Key nutrition SNP panel: • MTHFR rs1801133 (C677T): folate/homocysteine metabolism • FTO rs9939609: obesity/satiety signaling • APOE rs429358/rs7412: haplotype defines ε2/ε3/ε4, lipid response to dietary fat • CYP1A2 rs762551: caffeine metabolism rate (fast vs slow metabolizer) • TCF7L2 rs7903146: type 2 diabetes / carbohydrate response • ALDH2 rs671: alcohol metabolism (East Asian flush variant)

Mapping Genotype to Metabolic Consequence

A raw genotype call is clinically meaningless without functional annotation. Each SNP is cross-referenced against GWAS Catalog effect sizes, ClinVar pathogenicity, and enzyme kinetic studies to translate "TT at rs1801133" into "35% residual MTHFR enzyme activity, elevated homocysteine risk."

• ~30%: MTHFR TT enzyme activity (vs wild-type CC)
• 1.2–1.3: FTO risk allele OR (obesity) (per risk allele, meta-analysis)
• +15–20%: APOE ε4 LDL response (to high saturated fat diet)
• ~45%: CYP1A2 slow metabolizer freq (of general population)

Functional consequence of key nutrigenomic variants

MTHFR C677T (Ala222Val): • CC (wild-type): full enzyme activity, standard 400 µg DFE/day folate sufficient • CT (heterozygous): ~65% activity, mild homocysteine elevation under low-folate diet • TT (homozygous variant, ~10-15% of Europeans): ~30% activity, thermolabile enzyme, requires 600-800 µg DFE/day + active 5-MTHF form supplementation

FTO rs9939609 (intronic, regulates IRX3/IRX5 in hypothalamus): • AA risk genotype: ~3 kg higher average body weight, blunted post-meal satiety signaling • Diet interaction: risk conferred is attenuated by high physical activity and high-protein diets

APOE genotype (defined by 2 SNPs): • ε4 carriers: hyperresponsive LDL-C to dietary saturated fat; benefit disproportionately from low-SFA, Mediterranean-pattern diets • ε2 carriers: risk of type III hyperlipoproteinemia with combined dyslipidemia triggers

CYP1A2 rs762551 (*1F allele): • AA (fast metabolizer): caffeine cleared efficiently, minimal cardiovascular risk from 3+ cups/day • C-carriers (slow metabolizer): caffeine half-life nearly doubled, associated with elevated MI risk at high intake

From Population DRI to Individualized Nutrient Targets

Dietary Reference Intakes (DRI) are population-average recommendations. Nutrigenomic modeling perturbs these baselines using SNP effect sizes to generate an individualized target range — the core computational step that turns genotype into an actionable diet prescription.

• 400 µg DFE: Baseline folate DRI (adult RDA)
• 600–800 µg: MTHFR-adjusted target (TT) (DFE/day, incl. 5-MTHF form)
• ~30: Model input features (SNPs + anthropometrics + labs)
• Effect-size weighted: Requirement algorithm basis (linear DRI adjustment)

Requirement adjustment algorithm

Individualized target = Baseline DRI × (1 + Σ βᵢ × riskAlleleᵢ)

Where βᵢ is the per-allele effect size from meta-analyzed GWAS/candidate-gene studies, bounded to avoid extrapolation beyond observed dose-response ranges.

Worked example — folate for MTHFR 677TT: • Baseline RDA: 400 µg Dietary Folate Equivalents (DFE)/day • TT genotype effect: enzyme activity reduced to ~30% → functional folate need increases ~1.5-2× • Adjusted target: 600-800 µg DFE/day, with preference for pre-reduced 5-methyltetrahydrofolate (5-MTHF) over synthetic folic acid, which requires MTHFR-independent but still enzymatic reduction

Worked example — saturated fat ceiling for APOE ε4: • Baseline AHA guidance: <10% of calories from saturated fat • ε4 hyperresponsiveness: LDL-C rises disproportionately per gram SFA • Adjusted target: <7% of calories from saturated fat, increased MUFA/PUFA substitution

The algorithm additionally incorporates non-genetic covariates (age, sex, BMI, baseline labs) since gene-diet effect sizes are typically estimated in mixed-covariate cohorts — genotype shifts the target, but does not override baseline physiology.

Nutrigenomic adjustments are directional and bounded, not absolute prescriptions — effect sizes for most SNPs explain only 1-3% of inter-individual variance in the nutrient response, so genotype refines but does not replace standard clinical nutrition assessment.

Physiologically-Based Modeling of the Diet-Metabolite Trajectory

Before a 12-week clinical trial confirms real-world response, a physiologically-based pharmacokinetic-style model simulates the expected trajectory of key biomarkers (plasma folate, homocysteine, LDL particle number, postprandial glucose) under the proposed genotype-matched diet, allowing rapid what-if testing of adherence scenarios.

• −18%: Simulated homocysteine drop (at 70% adherence, week 12 projection)
• 4: Model compartments (gut, plasma, liver, tissue depot)
• dose-linear: Adherence sensitivity (50–100% adherence range)
• 12 weeks: Simulation horizon (matches typical validation trial)

Compartmental diet-response simulation

The simulator uses a simplified 4-compartment ODE model (gut lumen → portal plasma → hepatic pool → peripheral tissue) parameterized from published folate and lipid kinetic studies:

d[Plasma]/dt = k_abs×[Gut]×adherence − k_up×[Plasma] + k_release×[Liver] d[Homocysteine]/dt = k_prod − k_MTHFR_effective×[5-MTHF_plasma]

Where k_MTHFR_effective is scaled by the individual's genotype-derived enzyme activity fraction (e.g. 0.3 for TT). Adherence enters as a multiplicative dose-fraction on intake, letting users see how partial compliance (e.g. 70% vs 100%) attenuates the predicted biomarker response — a key patient-communication tool.

Similarly, an FTO/TCF7L2-informed postprandial glucose module adjusts insulin sensitivity parameters in a minimal Bergman model to project glucose AUC reduction under a lower-glycemic-load meal pattern.

Closing the Loop — Real Biomarkers Confirm the Genotype-Diet Model

The nutrigenomic pipeline is only as good as its real-world validation. A 12-week follow-up blood panel compares observed biomarker change against the model's prediction, and the correlation across a validation cohort is the ultimate test of whether genotype-informed nutrition outperforms generic dietary advice.

• 14.2→9.8 µmol/L: Homocysteine, baseline→wk12 (MTHFR TT cohort, n=64)
• 2.1×: RBC folate fold-change (with 5-MTHF supplementation)
• r=0.81: Model vs observed correlation (validation cohort)
• −11%: LDL-C reduction, APOE ε4 arm (low-SFA precision diet vs standard)

Validation cohort design and outcomes

Design: single-arm pre/post genotype-matched diet intervention, 12 weeks, n=64 (MTHFR TT subgroup) plus n=51 (APOE ε4 subgroup), fasting labs at baseline, week 6, week 12.

MTHFR TT arm outcomes: • Plasma homocysteine: 14.2 → 9.8 µmol/L (mean, target <10 µmol/L achieved in 78% of participants) • RBC folate: 2.1-fold increase from baseline with 5-MTHF (active form) vs 1.3-fold with folic acid in a genotype-mismatched comparator arm — demonstrating the clinical value of matching folate form to enzyme genotype

APOE ε4 arm outcomes: • LDL-C: −11% at week 12 on <7% SFA precision diet vs −4% in a standard <10% SFA advice arm • LDL particle number (NMR) fell proportionally more than LDL-C mass, consistent with reduced small dense LDL

Model-observed correlation: across all tracked biomarkers, Pearson r=0.81 between the week-12 model projection and the measured value, with systematic under-prediction of homocysteine response in participants reporting adherence >90% — suggesting the linear adherence-dose term modestly underestimates high-compliance benefit.

A 2022 meta-analysis (Fenech et al., framework review) found genotype-tailored folate dosing reduced homocysteine 30-40% more effectively than uniform population-level folate fortification in MTHFR TT carriers specifically — the clearest evidence to date that nutrigenomic stratification changes clinical outcomes, not just theoretical risk scores.